CAR-T (Allogeneic)
Memory NK (Allogeneic)
-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T…
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML —…
-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- …
Wugen is a clinical-stage biotechnology company
Cellular therapies originating from healthy donors
Come join our growing teams in San Diego and St. Louis